• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人对六甲蜜胺的口服吸收存在个体差异。

Variable oral absorption of hexamethylmelamine in man.

作者信息

D'Incalci M, Bolis G, Mangioni C, Morasca L, Garattini S

出版信息

Cancer Treat Rep. 1978 Dec;62(12):2117-9.

PMID:109196
Abstract

Plasma levels of hexamethylmelamine were measured by a sensitive and specific gas chromatographic assay in 11 patients after they received oral doses ranging from 120 to 300 mg/m2. Peak levels were reached in 0.5--3 hours and ranged from 0.2 to 20.8 micrograms/ml. The area under the curve ranged from 70.2 to 3606.6 micrograms/ml x minute. The half-life of the beta-phase of elimination also showed considerable variability, ranging between 4.66 and 10.2 hours. These parameters were not related to the dose administered. No plasma accumulation of the drug was observed after daily treatment with hexamethylmelamine for 14--21 days.

摘要

采用灵敏且特异的气相色谱分析法测定了11例患者口服剂量为120至300mg/m²后血浆中六甲蜜胺的水平。在0.5至3小时达到峰值水平,范围为0.2至20.8微克/毫升。曲线下面积范围为70.2至3606.6微克/毫升×分钟。消除β相的半衰期也显示出相当大的变异性,在4.66至10.2小时之间。这些参数与给药剂量无关。在六甲蜜胺每日治疗14至21天后,未观察到药物在血浆中的蓄积。

相似文献

1
Variable oral absorption of hexamethylmelamine in man.人对六甲蜜胺的口服吸收存在个体差异。
Cancer Treat Rep. 1978 Dec;62(12):2117-9.
2
Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation.
Cancer Res. 1990 Jan 1;50(1):206-10.
3
Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
Cancer Treat Rep. 1981 Sep-Oct;65(9-10):755-62.
4
Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.六甲蜜胺和五甲蜜胺在小鼠体内的药代动力学
Cancer Treat Rep. 1981 Jul-Aug;65(7-8):669-72.
5
A sensitive and specific assay for pentamethylmelamine in plasma: applicability to clinical studies.血浆中五甲基三聚氰胺的灵敏且特异的检测方法:在临床研究中的适用性。
Cancer Treat Rep. 1980 Jan;64(1):99-104.
6
Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers.六甲蜜胺在卵巢癌及其他盆腔癌患者中的分布情况。
Cancer Treat Rep. 1982 Feb;66(2):231-5.
7
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.六甲蜜胺用于铂耐药和铂难治性卵巢癌:妇科肿瘤学组II期试验
Gynecol Oncol. 1998 Jun;69(3):226-9. doi: 10.1006/gyno.1998.5016.
8
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.司他铂(JM216)的药代动力学,这是一种口服铂(IV)配合物,每日口服给药5天或14天。
Anticancer Res. 2003 May-Jun;23(3C):2757-65.
9
Cerebrospinal fluid and blood concentrations of toltrazuril 5% suspension in the horse after oral dosing.口服给药后马体内5%托曲珠利混悬液的脑脊液和血液浓度。
Vet Ther. 2000 Spring;1(2):125-32.
10
Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.
Cancer Treat Rep. 1979 Aug;63(8):1375-7.

引用本文的文献

1
Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).CI-994(CL-994的校正形式)(N-乙酰二苯胺)的临床前药代动力学、抗肿瘤及毒性研究。
Invest New Drugs. 1997;15(3):187-94. doi: 10.1023/a:1005846026398.
2
Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research.身体成分是抗癌药物药代动力学中的一个重要变量吗?综述及进一步研究建议。
Cancer Chemother Pharmacol. 1994;34(1):3-13. doi: 10.1007/BF00686105.
3
Clinical pharmacokinetics of altretamine.
Clin Pharmacokinet. 1995 Jun;28(6):439-48. doi: 10.2165/00003088-199528060-00002.
4
Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.六甲蜜胺。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1995 Jun;49(6):932-53. doi: 10.2165/00003495-199549060-00007.
5
The practical benefits of pharmacokinetics in the use of antineoplastic agents.药代动力学在抗肿瘤药物使用中的实际益处。
Cancer Chemother Pharmacol. 1980;4(3):139-45. doi: 10.1007/BF00254011.
6
Hexamethylmelamine and hexamethylmelamine hydrochloride.
Pharm Weekbl Sci. 1982 Apr 23;4(2):25-31. doi: 10.1007/BF01963657.
7
Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.六甲蜜胺及其代谢产物体外细胞毒性的时间依赖性。
Br J Cancer. 1980 Apr;41(4):630-5. doi: 10.1038/bjc.1980.106.
8
Human central nervous system pharmacology of pentamethylmelamine and its metabolites.五甲基三聚氰胺及其代谢产物的人体中枢神经系统药理学
J Neurooncol. 1983;1(4):357-64. doi: 10.1007/BF00165719.
9
Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.六甲蜜胺在荷卵巢癌小鼠体内的分布、代谢及不可逆结合
Cancer Chemother Pharmacol. 1983;11(1):51-5. doi: 10.1007/BF00257418.
10
Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.卵巢癌细胞体外药敏的临床相关性
Br J Cancer. 1983 Jul;48(1):61-8. doi: 10.1038/bjc.1983.157.